FDA expands approval of Blincyto for treatment of a type of leukemia in patients who have a certain risk factor for relapse
If your email program has trouble displaying this email, view it as a web page |
U.S. Food and Drug Administration |
If your email program has trouble displaying this email, view it as a web page |
| ||||||||||||||||||||||||||||||||||
U.S. Food and Drug Administration |
Comments
Post a Comment